Renal Cell Carcinoma Protocols
MULTI-001 Nivolumab v11
MULTI-003 Pembrolizumab v12
MULTI-018 Larotrectinib v2
MULTI-019 Entrectinib v2
MULTI-022 Ipilimumab in combination with Nivolumab for CRC and RCC v4
MULTI-027 Cabozantinib (Cabometyx®) v2
RCC-002 Sunitinib v6
RCC-003 Pazopanib v7
RCC-005 Axitinib v4
RCC-008 Lenvatinib (Kisplyx®) & Everolimus (Afinitor®) v1
RCC-009 Tivozanib v3
RCC-011 Avelumab and axitinib v2
RCC-012 Lenvatinib (Kisplyx®) with pembrolizumab v2
RCC-013 Cabozantinib (Cabometyx®) with nivolumab v1
MULTI-003 Pembrolizumab v12
MULTI-018 Larotrectinib v2
MULTI-019 Entrectinib v2
MULTI-022 Ipilimumab in combination with Nivolumab for CRC and RCC v4
MULTI-027 Cabozantinib (Cabometyx®) v2
RCC-003 Pazopanib v7
RCC-005 Axitinib v4
RCC-008 Lenvatinib (Kisplyx®) & Everolimus (Afinitor®) v1
RCC-009 Tivozanib v3
RCC-011 Avelumab and axitinib v2
RCC-012 Lenvatinib (Kisplyx®) with pembrolizumab v2
RCC-013 Cabozantinib (Cabometyx®) with nivolumab v1